Keytruda, scientifically known as pembrolizumab, is a prescription medicine used in immunotherapy for the treatment of various types of cancer.
What is Keytruda (Pembrolizumab)?
Keytruda, scientifically known as pembrolizumab, is a prescription medicine used in immunotherapy for the treatment of various types of cancer. It belongs to a class of drugs called PD-1 inhibitors. Keytruda works by harnessing the body's own immune system to recognize and fight cancer cells, marking a significant advancement in modern oncology.
Developed by Merck, Keytruda has received approval for treating a growing number of cancers, either as a standalone therapy or in combination with other treatments. Its mechanism of action represents a paradigm shift from traditional chemotherapy, focusing instead on reactivating the body's natural defenses.
How Keytruda Works: The PD-1 Pathway
Cancer cells can sometimes evade the immune system by expressing proteins that "turn off" immune cells, particularly T-cells. One common way they do this is by activating the PD-1 (Programmed Death-1) pathway. T-cells have PD-1 receptors on their surface, and when these receptors bind to PD-L1 (Programmed Death-Ligand 1) proteins found on cancer cells, the T-cells become inactivated.
Keytruda is an antibody that specifically blocks the PD-1 receptor on T-cells. By doing so, it prevents cancer cells from "turning off" the immune response. This unblocks the T-cells, allowing them to reactivate, recognize the cancer cells as foreign, and effectively attack and destroy them. This targeted approach is why Keytruda is considered a form of precision medicine.
Approved Uses of Keytruda in Cancer Treatment
Keytruda has been approved for the treatment of a wide range of cancers, often after other therapies have been tried or in specific stages of the disease. The approved indications continue to expand as research progresses.
Melanoma
Keytruda is used to treat unresectable or metastatic melanoma and as adjuvant treatment for melanoma with lymph node involvement following complete resection.
Non-Small Cell Lung Cancer (NSCLC)
It is a frontline treatment for metastatic NSCLC, either alone or in combination with chemotherapy, and for patients with advanced NSCLC who have progressed on other therapies.
Head and Neck Squamous Cell Carcinoma (HNSCC)
Keytruda is approved for recurrent or metastatic HNSCC, either as a first-line treatment or after platinum-containing chemotherapy.
Classical Hodgkin Lymphoma (cHL)
It is used in adult and pediatric patients with cHL that is refractory or relapsed after multiple lines of therapy.
Urothelial Carcinoma
Keytruda is indicated for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy, or who have progressed after platinum-containing chemotherapy.
Other Approved Indications
Keytruda is also approved for treating various other cancers, including certain types of kidney cancer (renal cell carcinoma), gastric cancer, esophageal cancer, cervical cancer, liver cancer (hepatocellular carcinoma), and certain cancers with specific biomarkers like microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) tumors.
Administration and Dosage
Keytruda is administered intravenously (into a vein) by a healthcare professional, typically over approximately 30 minutes. The dosage and frequency depend on the specific cancer being treated, the patient's body weight, and their response to the treatment. It is usually given every three or six weeks, as determined by the treating physician.
Potential Side Effects of Keytruda
As with all potent medications, Keytruda can cause side effects. These occur because the immune system, once activated, can sometimes attack healthy cells in addition to cancer cells. It is crucial for patients to report any new or worsening symptoms to their healthcare team promptly.
Common Side Effects
Some of the more common side effects include fatigue, nausea, diarrhea, rash, itching, decreased appetite, joint pain, and constipation. These are generally manageable and monitored by healthcare providers.
Serious Immune-Mediated Side Effects
More serious, but less common, side effects include immune-mediated inflammation of various organs. These can affect the lungs (pneumonitis), colon (colitis), liver (hepatitis), hormone-producing glands (endocrinopathies such as thyroid problems, adrenal insufficiency, or type 1 diabetes), kidneys (nephritis), and skin. Early detection and management of these side effects are vital to prevent severe complications.
Important Considerations for Patients
Before starting Keytruda, patients should discuss their full medical history with their doctor, including any autoimmune conditions, organ transplant history, or other medications they are taking. During treatment, regular monitoring through blood tests and physical examinations is essential to detect and manage potential side effects.
Keytruda represents a powerful tool in the fight against cancer, offering new hope for many patients. However, it is a complex therapy that requires careful consideration and management by experienced medical professionals.